Spruce biosciences reports first quarter 2023 financial results and provides corporate updates

South san francisco, calif.--(business wire)---- $sprb--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended march 31, 2023 and provided corporate updates. “i am pleased by the meaningful progress spruce made across our clinical and business objectives in the first quarter of 2023. patient enrollment i.
SPRB Ratings Summary
SPRB Quant Ranking